PROTAC development gains momentum, but clinical performance is poor
Pharmaceutical Technology
FEBRUARY 13, 2023
The first concept for a PROTAC was published in 2001, and recently these protein degraders have gained rapid momentum as a promising novel modality. This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active.
59 
Let's personalize your content